stockrow
Saturday 7 November 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
7.15
0.71
+11.02%
Follow AGEN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 6 | 5 |
| 0.03% | (23.40%) | (33.86%) | (14.99%) | ||
| (0.04%) | 33.31% | 51.30% | 12.29% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.06% | (46.32%) | (66.19%) | (71.00%) | |
Average Days of Receivables |
22.41 | 159.31 | 151.84 | 0.00 | |
Free Cash Flow per Share |
(2.58) | (2.30) | (2.37) | (1.66) | |
Free Cash Flow |
(76.84) | (87.14) | (98.16) | (103.86) | |
Capital Expenditures |
0.35 | 0.39 | 0.35 | — | |
| Other line items | |||||
Cash ROIC |
33.38% | 53.53% | 62.50% | 499.65% | |
Accounts Receivable Turnover |
30.79 | 4.55 | 4.75 | 0.00 | |
Accounts Payable Turnover |
0.01 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
29,638.21 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
69.48% | 56.22% | 43.47% | 34.15% | |
Selling, General and Administrative Expense of Revenue |
47.63% | 36.76% | 29.00% | 26.92% | |
Share Based Compensation of Revenue |
12.06% | 9.19% | 8.60% | 8.29% | |
Interest Coverage |
(0.36) | 0.14 | 0.61 | 0.86 | |
Operating CF/Net income |
764.31 | (1.36) | (1.07) | (3.53) | |
Depreciation/Fixed assets |
0.65 | 0.49 | 0.33 | 0.16 | |
Capex/Depreciation |
0.04 | 0.05 | 0.07 | 0.00 | |
Revenue per Share |
3.84 | 3.26 | 3.21 | 2.14 | |
Operating CF per Share |
(2.60) | (2.31) | (2.38) | (1.66) | |
Capex per Share |
0.01 | 0.01 | 0.01 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 5 Nov 2026